Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Presenter Treatment Optimisation Study (LAPTOP)
2023-505167-36-00Phase 3Completed
- Sponsor
- NEAT ID Foundation
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Integrase inhibitor-based ART (Biktarvy) with Boosted protease inhibitor-based ART (Symtuza) (2 arms). Primary endpoint: Time to failure. Started Nov 2023; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-505167-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505167-36-00.